Genalive, a leading clinical laboratory in Saudi Arabia, has passed an audit organized by the College of American Clinical Pathologists (CAP), demonstrating its excellence in clinical laboratory testing and management practices.
Genalive officially opened in June 2023, equipped with high-throughput sequencing platforms, advanced bioinformatics pipelines, AI-driven analytical tools and staffed by a team of experienced medical professionals and technicians. Genalive is a joint venture between BGI Almanahil Health for Medical Services, a wholly owned subsidiary of BGI Genomics, and Tibbiyah Holding, a renowned Saudi healthcare company.
CAP audit is an internationally recognized quality mark for medical laboratories, with an audit process that includes a comprehensive evaluation of laboratory equipment, staff training, sample handling, data management and quality control. Audit results indicate that Genalive has excelled in every phase of the audit, receiving recognition for its accurate laboratory testing and careful management of patient samples.
This laboratory, strategically located in central Riyadh, offers a wide range of services such as newborn genetic screening, non-invasive cancer screening, oncology, immunology services and clinical pathology.
Laboratory director Dr. Yusra Alyafee mentions: “These CAP audit results are a vote of confidence in Genalive. Our goal is to enhance health outcomes in line with Saudi Vision 2030. With BGI Genomics support, we will continue to localize tests and sample-handling within the Kingdom, minimize outsourcing of services, reduce risks and offer more accessible solutions to our patients.”
Mr. Ma Zhe, General Manager of BGI Genomics West Asia, said, “We are very proud of this accreditation. Such achievement proves that our team possesses extensive medical expertise and excels in the delivery and quality control of medical testing services. BGI Genomics will continue to provide high-quality services, reliable diagnostic results and the best possible care to our patients in Saudi Arabia and neighboring countries.”
About BGI Genomics:
BGI Genomics, headquartered in Shenzhen, China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.
